Clinical trials
Immunization clinical trials
Below are recruiting immunization clinical trials, each written for real people, not researchers. We’re tracking 973 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06475807Recruiting
Dietary changes for people on immunotherapy for cancer
This study tests whether a change in diet can help people with early-stage melanoma or lung cancer who are receiving immunotherapy (a type of treatment that helps your immune system fight cancer). You will be asked to follow a diet, give blood and stool samples, and complete questionnaires to see how the diet affects your body and treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06469190RecruitingEarly Phase 1
CAR NK cells for treatment-resistant kidney disease
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
ShanghaiAges 18–70 - NCT06453460RecruitingPhase 2
Preventing CMV with letermovir after stem cell transplant
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Orange, CaliforniaAges 18 years+ - NCT06401720Enrolling by invitation
Flu immune response study by age
This study looks at how the immune system reacts to the flu in people of different ages. If you have flu symptoms and don't have cancer or take immune-suppressing drugs, you may be able to join.
SödertäljeAges 18 years+ - NCT06413004Recruiting
IBS and immune reactions to bacteria in the gut
This study tests whether some IBS symptoms are linked to a certain gut bacteria and an immune reaction. It aims to understand the cause of IBS to find better treatments.
GothenburgAges 18–70 - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Denver, ColoradoAges 18–80 - NCT04280510Recruiting
Study of immune-related gut illnesses in adults
This study looks at adults with immune-related stomach and intestine problems to better understand what may cause them. If you qualify, you can share information and consent to help researchers learn how these conditions work.
CréteilAges 18 years+ - NCT06379256Recruiting
Liver cancer radiation and immune response study
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
Taoyuan City, TaiwanAges 18 years+ - NCT05534009Recruiting
Study of healthcare workers’ COVID infection and vaccine history
This study gathers information about healthcare workers (adults) and tracks your past COVID-19 infection and vaccination history. It may help researchers understand how COVID affects healthcare workers and how vaccines relate to infection outcomes.
DüsseldorfAges 18 years+ - NCT06368141RecruitingPhase 2
Chemo plus immunotherapy before surgery for colon cancer
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06329453Recruiting
Gut immunity and brain health study
This study looks at how your gut's immune system relates to brain and nerve diseases. Researchers will collect samples during a colonoscopy to better understand connections between gut health and neurologic conditions like multiple sclerosis or Parkinson's disease.
North Haven, ConnecticutAges 18–99 - NCT06337695RecruitingPhase 2/Phase 3
Preventing immunotherapy-related diarrhea in advanced cancer
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Calgary, AlbertaAges 18 years+ - NCT06305234Recruiting
Long-term immune response study for Palynziq PKU treatment
This long-term study checks how the immune system reacts to Palynziq (a treatment for PKU) over time. It involves extra blood tests for people already in another PKU study called 165-501.
Aurora, ColoradoAges Any age - NCT06069583Recruiting
Support program for adults with type 1 diabetes
This trial tests an online support platform to help adults with type 1 diabetes manage their condition. If you live in Canada, have internet access, and can read English or French, you may be able to join.
Montreal, QuebecAges 18 years+ - NCT06290505RecruitingPhase 2
Palliative therapy for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (durvalumab) for esophageal cancer that has spread to a few other places in the body or is too advanced for surgery. It aims to see if this combination helps with swallowing difficulties and slows the cancer's growth.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06279130RecruitingPhase 2/Phase 3
New immunotherapy before surgery for multiple cancer types
This trial tests new immunotherapy combinations given before surgery for cancers that have certain genetic features (dMMR or pMMR). It aims to see if these drugs can shrink tumors and improve outcomes for patients with various cancer types, including those for which standard neoadjuvant therapy is not an option.
Amsterdam, North HollandAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06285539RecruitingPhase 2
Testing a drug for rare inflammatory diseases
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
AmsterdamAges 18–65 - NCT06247150Recruiting
Study of immune cells in graft-versus-host disease after stem cell transplant
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
PessacAges 18 years+
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization?
- Yes. Clin2 currently lists 973 recruiting immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.